AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US
- Conditions
- COPD
- Interventions
- Drug: Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.Other: External Comparator
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05970263
A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
- Conditions
- Renal Disease
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2575
- Registration Number
- NCT05967806
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT05966324
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT05961397
- Locations
- 🇺🇸
American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Inland Empire Clinical Trials, Rialto, California, United States
Baxdrostat Bioavailability and Bioequivalence Study
- Conditions
- Hypertension
- Interventions
- Drug: baxdrostat (formerly CIN-107) oral solution
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT05963009
- Locations
- 🇺🇸
Medpace, Cincinnati, Ohio, United States
Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT05961384
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States
Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT05958134
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT05955183
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics
- Conditions
- Chronic Kidney Diseases
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800211
- Registration Number
- NCT05953701
- Locations
- 🇩🇪
Research Site, Koblenz, Germany
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT05952024
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico